We evaluated the risk factors associated with oral human papillomavirus (HPV) infection and oral lesions in 161 human immunodeficiency virus (HIV)-positive patients and 128 HIV-negative patients presenting for oral examination at 2 urban healthcare centers. Patients were interviewed on risk factors and provided oral-rinse samples for HPV DNA typing by polymerase chain reaction. Statistical associations were assessed by logistic regression. Oral HPV was prevalent in 32% and 16% of HIV-positive patients and HIV-negative patients, respectively, including high-risk HPV type 16 (8% and 2%, respectively; P = .049) and uncommon HPV types 32/42 (6% and 5%, respectively; P = .715). Among HIV-negative patients, significant risk factors for oral HPV included multiple sex partners (≥21 vs ≤5; odds ratio [OR], 9.1; 95% confidence interval [CI], 1.7-49.3), heavy tobacco smoking (>20 pack-years vs none; OR, 9.2; 95% CI, 1.4-59.4), and marijuana use (OR, 4.0; 95% CI, 1.3-12.4). Among HIVpositive patients, lower CD4 + T-cell count only was associated with oral HPV detection (≤200 vs ≥500 cells/ mm 3 ; OR, 4.5; 95% CI, 1.3-15.5). Detection of high-risk HPV was also associated with concurrent detection of potentially cancerous oral lesions among HIV-negative patients but not among HIV-positive patients. The observed risk factor associations with oral HPV in HIV-negative patients are consistent with sexual transmission and local immunity, whereas in HIV-positive patients, oral HPV detection is strongly associated with low CD4 + T-cell counts.
dentistry, otolaryngology, oral medicine, and oral surgery outpatient clinics at the Montefiore Medical Center (Bronx, New York) and Rutgers School of Dental Medicine (Newark, New Jersey) were invited to participate. Patients presenting between 2008 and 2013 for routine dental care to these health centers were matched on the basis of HIV serostatus, age (±10 years), and sex, when feasible. Pregnant females, minors, and patients with a history of treatment for cancer during the preceding year were excluded. The study protocol was approved by the institutional review boards at Albert Einstein College of Medicine, Montefiore Medical Center, and Rutgers University, and all subjects provided written informed consent before participating.
Study Interviews and Oral Examinations
All patients provided an oral rinse sample of 10 mL of Scope mouthwash after rinsing for 30 seconds. The oral rinse specimens were then stored at −20°C within 6 hours of collection until used for HPV testing. Each patient also underwent an oral examination by a collaborating clinician. The presence, type, and location of each oral lesion was recorded in a diagram. Potentially cancerous oral lesions detected included leukoplakia, erythroplasia, and erythro-leukoplakia [13] . Erythematous, hyperplastic, or pseudomembranous candidiasis, traumatic or denture ulcers, other aphthous or nonspecific ulcers, traumatic fibroma, geographic tongue, pyogenic granuloma, sinus fistula, pedunculated growth, pemphigus, reticular (nonatrophic) lichen planus, frictional keratosis, oral papillomas, and other nonspecific intraoral conditions were considered benign. Suspicious lesions were biopsied and underwent pathological review after consent was received from the patient. Biopsied lesions found to have dysplasia were classified as potentially cancerous. Lesion status was defined by the most severe lesion type detected.
Participants additionally underwent a structured interview to collect data on demographic characteristics (eg, age, sex, race, and ethnicity); tobacco, alcohol, and drug consumption history; sexual behavior history (ie, sexual orientation, practice of oral sex, and lifetime and recent number of sex partners); past dental history (ie, number of missing teeth, denture use, and history of oral biopsies); and history of sexually transmitted diseases, anogenital warts, and cancer.
T-helper cell or CD4 + T-cell counts and plasma HIV RNA level measurements within 6 months of enrollment were obtained from medical records. The immune status of HIV-positive patients was determined on the basis of their CD4 + T-cell counts and HIV loads. For the few cases with missing data for viral load, only CD4 + T-cell counts were considered for classification.
Use of highly active antiretroviral therapy (HAART) was defined as a regimen that contained 2 nucleoside/nucleotide reverse-transcriptase inhibitors and either a protease inhibitor, a nonnucleoside reverse-transcriptase inhibitor, or an integrase inhibitor or as a regimen that combined 3 different classes of HIV medications. New drug combinations introduced during the course of the study (eg, Complera) were also accounted for in the definition of HAART.
HPV DNA Testing
We previously demonstrated that HPV can be detected in oral rinse specimens with reproducibility in self-collected and inclinic samples taken 4-8 hours apart [14] . Briefly, genomic DNA was extracted using a previously described protocol [15] , and purified DNA was amplified by a MY09/MY11 L1 degenerate primer polymerase chain reaction (PCR) system, using Gold Taq Polymerase (Applied Biosystems, California) [16, 17] . PCR products were separated by gel electrophoresis and hybridized with radiolabeled generic HPV and β-globin probes. Four subjects were excluded owing to insufficient material for HPV genotyping. HPV-positive samples were genotyped by dot-blot hybridization, using biotinylated type-specific oligonucleotide probes for HPV alpha types. Strict protocols to prevent crosscontamination and false-positive reactions were followed, and laboratory personnel were blinded to clinical data.
HPV types were grouped into low-risk types ( [18] . PCR products that were positive by the generic probe mix but negative by all type-specific probes were considered to represent low-risk HPV types.
Statistical Analyses
Differences in distribution of risk factors between HIV-positive patients and HIV-negative patients and between men and women were assessed by χ 2 tests and tests for trend. Associations between oral HPV detection and the various risk factors among HIV-positive patients and HIV-negative patients were estimated by odds ratios (ORs) with 95% confidence intervals (CIs) derived by logistic regression. Multivariate risk models for HPV detection were built using stepwise selection, assuming a P value cut point of <.2, with adjustment a priori for age and sex. We tested for effect modification (interaction) between HIV and significant risk factors for oral HPV detection by fitting the multivariate models combining HIV-positive patients and negative patients, including a cross-product with HIV. Additional testing for effect modification by sex was also done using this approach. Inference was based on the Wald χ 2 test statistic for 2-way interaction.
RESULTS
A total of 289 adults with mean age of 50.8 years (range, 21-80 years) were enrolled into the study; 161 were HIV positive, and 128 were HIV negative. Most subjects identified themselves as Hispanic (33%) or African American (50%). Table 1 describes the study population characteristics, by HIV serostatus. HIVpositive patients had significantly more sex partners (oral and anogenital intercourse), inferior oral health (including missing teeth and concurrent oral lesions), a more-extensive and current history of cigarette smoking, and a higher likelihood of smoking marijuana than HIV-negative patients. The distributions of HPV types detected in HIV-positive patients and HIV-negative patients are shown in Figure 1 . Oral HPV DNA was detected in 32% and 16% of HIV-positive patients and HIV-negative patients, respectively (P = .002). Multiple concurrent HPV types (range, 2-6 types) were detected in 30 subjects (10%), representing 13% and 7% of HIV-positive patients and HIV-negative patients, respectively. HIV positivity was also significantly associated with detection of high-risk HPV types (17% vs 4%; P < .0005). No difference in HPV detection was found between the 2 participating institutions among HIV-positive patients (P = .375) and HIV-negative patients (P = .171). Table 2 describes the associations between participant characteristics and detection of oral HPV DNA in HIV-positive patients and HIV-negative patients. There were a number of differences in risk factors for oral HPV detection between HIV-positive patients and HIV-negative patients. Among HIV-negative patients, significant associations with oral HPV detection were found with higher lifetime number of sex Statistical evidence for effect modification by HIV serostatus was found for lifetime number of sex partners (adjusted P value for interaction = 0.033), tobacco smoking (P = .055), and drug use (P = .005). Younger age (<50 vs ≥50 years) was also associated with oral HPV detection but remained significant only for HIV-negative patients after adjustment for other factors. While power was limited to assess individual HPV types separately, similar differences in association, by HIV serostatus, to those presented in the adjusted models in Table 2 were observed for high-risk HPV types and low-risk HPV types (Supplementary Table 1 ). We also assessed differences according to sex. Men were more likely than women to have a higher lifetime number of sex partners (P = .000), to have engaged in oral sex (P = .010), to report having had homosexual or bisexual relationships (P = .000), and to have smoked tobacco (P = .010) or marijuana (P = .000).
Similar associations to those presented in the adjusted models were seen for men and women separately, except for sexual preference. In particular, HIV-positive bisexual and heterosexual men (OR, 3.4; 95% CI, 1.5-7.9), as well as women who had sex with women (OR, 3.2; 95% CI, .8-12.6) were more likely to have oral HPV detected than HIV-positive women who were exclusively heterosexual, although the associations were not significant after adjustment for CD4 + T-cell count. Tests for interaction between oral HPV risk factors and sex revealed no statistical evidence for effect modification among HIV-positive patients or HIV-negative patients (data not shown). Next, we evaluated the association between concurrent detection of oral HPV and lesions in HIV-positive patients and HIVnegative patients. Among patients presenting with oral lesions, 15% (43) had potentially cancerous lesions, 3% (8) had oral papillomas, and 9% (26) had other benign lesions. Thirty patients presented with multiple concurrent oral lesions, of whom 7 had both precancerous and benign types. We assessed for risk factors associated with oral lesions by comparing patients presenting with potentially cancerous lesions to those with only benign or no lesions (Table 3 ). In HIV-negative patients, high-risk HPV types were detected more often in potentially cancerous The most frequent HPV types detected among patients with benign oral lesions and potentially cancerous lesions was HPV32/42, regardless of HIV status (Supplementary Table 2 ). Interestingly, of 8 papillomas detected, 4 were biopsied and found to be positive for the uncommon types HPV32/42 with positive dysplastic features, including nuclear pleomorphism, hyperchromasia, increased nuclear:cytoplasmic ratio, or cellular atypia. All dysplastic cases were included with the potentially cancerous lesions. Analyses that adjusted for HIV serostatus, sex, age, and concurrent detection of high-risk HPV types revealed that HPV32/42 types were more likely to be detected in patients with potentially cancerous oral lesions, compared with patients without lesions (OR, 4.3; 95% CI, 1.2-14.6). No significant associations were found for other individual HPV types.
DISCUSSION
Our findings suggest that there may be distinct risk factors involved with oral HPV detection in HIV-positive patients as compared to HIV-negative patients. In HIV-negative patients, age, sex, lifetime number of sex partners, tobacco smoking, and history of marijuana use indicated associations with oral HPV detection. These findings are in accordance with those from a literature review [12, 19, 20] . However, in HIV-positive patients, age, sex, and immunosuppression, as measured by CD4 + T-cell count, were the only factors significantly associated with detection of oral HPV. Whereas HIV-positive patients reported higher levels of sexual behavior, no associations were observed with increased sexual activity, after statistical adjustment for immune status.
A recent study with >5000 HIV-negative participants found that men were more likely to harbor oral HPV than women independent of other risk factors, including number of sex partners and current number of cigarettes smoked per day [21] . Reports of HIV-positive individuals have also found a higher prevalence of oral HPV in men versus women [22] [23] [24] [25] and among heterosexual/bisexual men versus men who had sex with men [11, 26] , suggesting vaginal-to-oral transmission as a primary mode of infection [27, 28] . Men in our study, irrespective of sexual orientation, and women who had sex with women were more likely, albeit not significantly, to have oral HPV, compared with women who were exclusively heterosexual. Increases in detection of oral lesions and cancer in HIV-positive patients have been attributed to the longer life expectancies of individuals receiving HAART [4, 5] . We previously reported a higher prevalence of oral HPV in HIV-positive patients with oral candidiasis and leukoplakia, compared with HIV-positive patients without lesions [14] . In this larger study of HIVpositive individuals and HIV-negative individuals, we found that the majority of cases of oral HPV detection involved patients with benign lesions (50%), compared with patients with potentially cancerous lesions (35%) and patients with no lesions (30%). A significant association with potentially cancerous lesions was seen for high-risk HPV types among HIV-negative patients. However, an association between oral HPV and incidence of cancer remains elusive [29] .
A novel finding in this study was the association between HPV32/42 and potentially precancerous lesions among both HIV-positive patients and HIV-negative patients, although we could not distinguish between the closely related HPV32 and HPV42 by means of the MY09/11 PCR protocol. HPV32 has been shown to establish infection by selectively enhancing epithelial cell growth and differentiation in the stratum spinosum and to evade the immune system by actively suppressing inflammatory responses in adjacent underlying tissues [30] .
Certain limitations should be taken into account in the interpretation of the current data. The most important limitation is the small sample size, which limited the study's power to assess multiple risk associations with oral lesions or to assess for differences in HPV detection by both sex and sexual orientation. Second, because this was a cross-sectional study, the history of oral HPV exposure prior to HIV infection and development of oral lesions is not known. Third, assessment of oral lesions was based primarily on visual examination, which is prone to misclassification, with histological confirmation conducted only on a subset of cases. The majority of lesions resolved on their own or were removed surgically. Therefore, the role of oral HPV in progression to oral cancer in HIV-positive individuals and HIV-negative individuals remains unclear [2] .
In conclusion, our study confirms previous reports that risk factors for oral HPV detection differ for HIV-positive individuals and HIV-negative individuals. Immune status appears to have a strong effect on oral HPV infection in HIV-positive individuals, which might mitigate the association with sexual risk factors. However, the high burden of oral HPV in both HIV-positive individuals and HIV-negative individuals suggests that the mouth may be a reservoir of subclinical HPV infection with the potential to contribute to future oral disease. In particular, oral infection with HPV may be associated with a subset of proliferative and premalignant lesions in the oral cavity [2] . These observations, coupled with the frequent detection of subclinical HPV in the oral cavity, may predict an increased risk of HPV-related oral disease [31, 32] . 
